C.L. van der Wilt - Concepedia

Author

C.L. van der Wilt

Also Known As

C L Van der Wilt, C L Wilt, C L van der Wilt, C Nina van der Wilt, C. L. Van Der Wilt, C. L. Van der Wilt, C. L. Wilt, C. L. van Der Wilt, C. L. van der Wilt, C. Nina van der Wilt

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

University of Amsterdam Vrije Universiteit Amsterdam Amsterdam UMC Location Vrije Universiteit Amsterdam The Netherlands Cancer Institute Center for Rheumatology

About

C.L. van der Wilt is an author at University of Amsterdam specializing in medicine, pharmacology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	26	1.5K
2	Biochemistry	7	7	162
3	Natural Sciences	5	5	112
4	Health Sciences	3	3	61
5	Biomolecular Engineering	1	1	12

C.L. van der Wilt

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers Paul Noordhuis, U. Holwerda, C.L. van der Wilt, Annals of Oncology Oncogenic AgentSynthase InhibitionMolecular BiologyColorectal CancerHuman Colorectal Cancers	2004	257
Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. Godefridus J. Peters, C.L. van der Wilt, C.J. van Groeningen, Journal of Clinical Oncology	1994	195
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Judith R. Kroep, Willem J.P Loves, C.L. van der Wilt, PubMed Vivo Gemcitabine SensitivityOncologyOncogenic AgentDck ActivityDck Expression	2002	191
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines Andries M. Bergman, Herbert M. Pinedo, Iannis Talianidis, British Journal of Cancer	2003	166
Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Baukelien van Triest, Herbert M. Pinedo, Yvette van Hensbergen, PubMed PathologyThymidylate SynthasePharmacotherapyPharmaceutical ChemistryMedicinal Chemistry	1999	145
Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. C.L. van der Wilt, Herbert M. Pinedo, Kees Smid, PubMed Tumor Biology5-Fluorouracil TreatmentOncologyColon 38Gastrointestinal Oncology	1992	120
First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma Anneke M. Westermann, Ellen L. Jones, Baard‐Christian Schem, Cancer	2005	118
Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma Godefridus J. Peters, J. Lankelma, Rob Kok, Cancer Chemotherapy and Pharmacology High ConcentrationsOncologyMedicineRadiopharmaceutical TherapyMurine Tumors	1993	106
Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed Godefridus J. Peters, Baukelien van Triest, Harold H.J. Backus, European Journal of Cancer Oncogenic AgentMedicineColorectal CancerThymidylate SynthaseTumor Suppressor	2000	88
Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. C.L. van der Wilt, Harold H.J. Backus, Kees Smid, Data Archiving and Networked Services (DANS)	2001	63

Page 1